NCT06393348View on ClinicalTrials.gov

Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

HRS-7535

HRS-7535

DRUG

Placebo

Placebo

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06393348 - Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i. | Biotech Hunter | Biotech Hunter